CSPC Pharmaceutical logo

1093 - CSPC Pharmaceutical Share Price

HK$9.01 0.1  0.9%

Last Trade - 9:08am

Large Cap
Market Cap £10.69bn
Enterprise Value £9.94bn
Revenue £2.72bn
Position in Universe 123rd / 5997
Unlock 1093 Revenue
Relative Strength (%)
1m -10.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -21.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
8,704 9,235 10,584 13,406 17,717 22,103 25,591 30,317 +20.5%
+43.9 +35.5 +32.2 +31.4 +25.0 +23.8 +18.7 +15.3
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, CSPC Pharmaceutical Group Ltd revenues increased 13% to RMB12.59B. Net income increased 23% to RMB2.31B. Revenues reflect Finished Drugs segment increase of 17% to RMB10.23B, Others segment increase of 21% to RMB875.6M. Net income benefited from Finished Drugs segment income increase of 17% to RMB2.19B, Others segment income increase of 54% to RMB195.6M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 1093
Graphical History


1093 Revenue Unlock 1093 Revenue

Net Income

1093 Net Income Unlock 1093 Revenue

Normalised EPS

1093 Normalised EPS Unlock 1093 Revenue

PE Ratio Range

1093 PE Ratio Range Unlock 1093 Revenue

Dividend Yield Range

1093 Dividend Yield Range Unlock 1093 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
1093 EPS Forecasts Unlock 1093 Revenue
Profile Summary

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated June 16, 1992
Public Since June 21, 1994
No. of Shareholders: n/a
No. of Employees: 17,292
Sector Healthcare
Industry Pharmaceuticals
Index Hang Seng Composite , Hang Seng , Hang Seng Composite LargeCap & MidCap , Hang Seng Mainland 100 ,
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 11,973,769,733
Free Float (0.0%)
Eligible for
1093 Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for 1093
Upcoming Events for 1093
Friday 13th November, 2020
CSPC Pharmaceutical Group Ltd Split For CSPCY.PK - Ratio 8-5
Monday 16th November, 2020 Estimate
Q3 2020 CSPC Pharmaceutical Group Ltd Earnings Release
Monday 29th March, 2021 Estimate
Full Year 2020 CSPC Pharmaceutical Group Ltd Earnings Release
Frequently Asked Questions for CSPC Pharmaceutical
What is the CSPC Pharmaceutical share price?

As of 9:08am, shares in CSPC Pharmaceutical are trading at HK$9.01, giving the company a market capitalisation of £10.69bn. This share price information is delayed by 15 minutes.

How has the CSPC Pharmaceutical share price performed this year?

Shares in CSPC Pharmaceutical are currently trading at HK$9.01 and the price has moved by -1.46% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CSPC Pharmaceutical price has moved by -1.74% over the past year.

What are the analyst and broker recommendations for CSPC Pharmaceutical?

Of the analysts with advisory recommendations for CSPC Pharmaceutical, there are there are currently 11 "buy" , 2 "hold" and 1 "sell" recommendations. The overall consensus recommendation for CSPC Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will CSPC Pharmaceutical next release its financial results?

CSPC Pharmaceutical is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the CSPC Pharmaceutical dividend yield?

The CSPC Pharmaceutical dividend yield is 1.65% based on the trailing twelve month period.

Does CSPC Pharmaceutical pay a dividend?

Last year, CSPC Pharmaceutical paid a total dividend of 0.13, and it currently has a trailing dividend yield of 1.65%. Looking ahead, CSPC Pharmaceutical has not announced an ex-dividend date yet.

When does CSPC Pharmaceutical next pay dividends?

CSPC Pharmaceutical has yet to annouce their ex-dividend date. The historic dividend yield on CSPC Pharmaceutical shares is currently 1.65%.

How do I buy CSPC Pharmaceutical shares?

To buy shares in CSPC Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CSPC Pharmaceutical?

Shares in CSPC Pharmaceutical are currently trading at HK$9.01, giving the company a market capitalisation of £10.69bn.

Where are CSPC Pharmaceutical shares listed? Where are CSPC Pharmaceutical shares listed?

Here are the trading details for CSPC Pharmaceutical:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 1093
What kind of share is CSPC Pharmaceutical?

Based on an overall assessment of its quality, value and momentum, CSPC Pharmaceutical is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CSPC Pharmaceutical share price forecast 2020?

Shares in CSPC Pharmaceutical are currently priced at HK$9.01. At that level they are trading at 18.33% discount to the analyst consensus target price of 0.00.

Analysts covering CSPC Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of 0.3792453939 for the next financial year.

How can I tell whether the CSPC Pharmaceutical share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CSPC Pharmaceutical. Over the past six months, the relative strength of its shares against the market has been -12.77%. At the current price of HK$9.01, shares in CSPC Pharmaceutical are trading at -2.82% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CSPC Pharmaceutical PE Ratio?

The CSPC Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 21.94. The shares are currently trading at HK$9.01.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of CSPC Pharmaceutical?

CSPC Pharmaceutical's management team is headed by:

Dongchen Cai - CHM
Ka Sze Lee - SEC
Siu Keung Chan - NID
Kin Man Chak - EDR
Weidong Pan - EDR
Huaiyu Wang - EDR
Zhenguo Wang - EDR
Bo Wang - NID
Yuk Lam Lo - NID
Jinming Yu - NID
Chuan Chen - NID
Chunlei Li - EDR
Cuilong Zhang - VCH
Qingxi Wang - EDR
Who are the major shareholders of CSPC Pharmaceutical?

Here are the top five shareholders of CSPC Pharmaceutical based on the size of their shareholding:

Cai (Dong Chen) Individual Investor
Percentage owned: 20.76% (1.55bn shares)
Massive Giant Group Ltd. Corporation
Percentage owned: 16.29% (1.22bn shares)
Common Success International Ltd. Corporation
Percentage owned: 9.63% (720.4m shares)
UBS (Luxembourg) S.A. Investment Advisor
Percentage owned: 4.89% (365.8m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.78% (282.7m shares)
Similar to 1093
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.